The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 30, 2010
Filed:
Nov. 12, 2007
Claudio D. Schteingart, San Diego, CA (US);
Frédérique Menzaghi, Rye, NY (US);
Guangcheng Jiang, San Diego, CA (US);
Roberta Vezza Alexander, San Diego, CA (US);
Javier Sueiras-diaz, La Jolla, CA (US);
Robert H. Spencer, New Hope, PA (US);
Derek T. Chalmers, Riverside, CT (US);
Zhiyong Luo, New City, NY (US);
Claudio D. Schteingart, San Diego, CA (US);
Frédérique Menzaghi, Rye, NY (US);
Guangcheng Jiang, San Diego, CA (US);
Roberta Vezza Alexander, San Diego, CA (US);
Javier Sueiras-Diaz, La Jolla, CA (US);
Robert H. Spencer, New Hope, PA (US);
Derek T. Chalmers, Riverside, CT (US);
Zhiyong Luo, New City, NY (US);
Cara Therapeutics, Inc., Shelton, CT (US);
Abstract
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.